This trial will evaluate if Flecainide Acetate, when inhaled, is more effective than a placebo in treating patients with recent onset atrial fibrillation. Approximately 400 people will be enrolled in the study and will be given either the drug or the placebo. The study will last for 24 weeks.
- Atrial Fibrillation
1 Primary · 5 Secondary · Reporting Duration: 90 minutes
Awards & Highlights
2 Treatment Groups
FlecIH-103 (flecainide acetate inhalation solution)
1 of 2
Vehicle-matched inhalation solution (placebo)
1 of 2
400 Total Participants · 2 Treatment Groups
Primary Treatment: FlecIH-103 (flecainide acetate inhalation solution) · Has Placebo Group · Phase 3
Who is running the clinical trial?
Age 18 - 85 · All Participants · 1 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Is FlecIH-103 (flecainide acetate inhalation solution) an FDA-verified medication?
"The safety of FlecIH-103 has been well documented in Phase 3 trials, so it received a score of 3 from our Power team." - Anonymous Online Contributor
Are people with the specific ailment needed for this clinical trial able to participate at this time?
"The study is looking for participants and has all the necessary information posted on clinicaltrials.gov. The trial was first posted on 4/26/2022 and updated on the same day, meaning that the data is recent and reliable." - Anonymous Online Contributor
Does this research exclude patients that are middle-aged or older?
"The age limit for patients participating in this study is 85 years old. So long as they are above 18, any patient is welcome." - Anonymous Online Contributor